Navigation Links
Lexicon to Report Second Quarter Financial Results on July 30, 2013
Date:7/23/2013

e operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2012, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Lexicon to Provide First Quarter 2012 Financial Results
2. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 First Quarter Results
3. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
4. Lexicon Pharmaceuticals to present at the Jefferies 2012 Global Healthcare Conference
5. Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
6. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
7. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
8. Lexicon to Provide Second Quarter 2012 Financial Results
9. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 Second Quarter Results
10. Lexicon Pharmaceuticals To Present At The Wedbush PacGrow 2012 Management Access Conference
11. Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... , May 29, 2015  Today, UL ... a leading global provider of electronic quality management ... collaborative agreement which will leverage the strengths of ... both quality system implementation and comprehensive advice and ... Adding MasterControl,s EQMS capabilities to UL,s strength in ...
(Date:5/29/2015)... PARAMUS, N.J. , May 29, 2015 A ... Business," is being presented at the Cannabis World ... in New York, NY .  Taking place ... of a dedicated day of education at the leading event ... industry. Led by Clover Leaf University, the ...
(Date:5/29/2015)... May 28, 2015 Research and Markets ... Jain PharmaBiotech,s new report "Cardiovascular Drug Delivery ... offering. Drug delivery to the cardiovascular ... because of the anatomy and physiology of the ... all organs of the body. Drugs can be ...
Breaking Medicine Technology:UL and MasterControl collaborate to provide medical manufacturers full service QMS and Regulatory Submissions support 2UL and MasterControl collaborate to provide medical manufacturers full service QMS and Regulatory Submissions support 3Cannabis Business Certification and Career Workshops Presented at New York Trade Show & Conference 2Cannabis Business Certification and Career Workshops Presented at New York Trade Show & Conference 3Cannabis Business Certification and Career Workshops Presented at New York Trade Show & Conference 4Global Cardiovascular Drug Delivery Market 2015 - Technologies, Markets and Companies 2Global Cardiovascular Drug Delivery Market 2015 - Technologies, Markets and Companies 3
(Date:5/30/2015)... CA (PRWEB) May 30, 2015 One ... the lack of local healthcare options available. Often, the ... adequate healthcare. For those in rural areas feeling the ... without health insurance or tired of paying high premiums ... E-consults, connecting patients with licensed physicians via the power ...
(Date:5/30/2015)... York, New York (PRWEB) May 30, 2015 ... to pay $100 million in punitive and compensatory ... ) plaintiff who suffered serious complications following implantation ... According to a verdict rendered on May 28th ... $25 million in compensatory damages after the jury ...
(Date:5/30/2015)... Texas (PRWEB) May 30, 2015 EHO ... Services Web Portal that gives hospices the ability to ... industry. Because of this business model, EHO has been ... better pricing to its clients and survive among the ... with hospice management systems three years ago, it has ...
(Date:5/30/2015)... 2015 Nicole Blodgett, Vice President ... Associate (DIA) designation to further her expertise in ... designed for insurance advisors, health care professionals, and ... and expertise associated with the risk and the ... is only the latest accomplishment in Nicole's journey ...
(Date:5/30/2015)... The Brain Fitness Education seminar was organized ... Enrichment Center, headed by 1Heart Client Care Manager Maria ... Fitness Program Director Tee Barr. , Senior residents of ... are many ways to enrich and further improve their ... different ways to overcome dementia and memory loss. During ...
Breaking Medicine News(10 mins):Health News:Online USA Doctors Brings Healthcare to the Masses with New E-Consults 2Health News:Online USA Doctors Brings Healthcare to the Masses with New E-Consults 3Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 2Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 3Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 4Health News:Secura Consultants Expands Disability Insurance Expertise 2Health News:1Heart Caregiver Services Brings Brain Fitness Education Seminar at ONEgeneration 2Health News:1Heart Caregiver Services Brings Brain Fitness Education Seminar at ONEgeneration 3
... The discovery 15 years ago that the genes BRCA1 ... cancer was a breakthrough for cancer prediction and therapy, ... Prof. Alfons Meindl (Klinikum rechts der Isar of the ... Germany, the U.K., and the U.S., can identify another ...
... likely to be screened, study finds , WEDNESDAY, April 21 ... are being screened for skin cancer, a particular problem among ... common cancer screenings, a new study has found. , Researchers ... and older, who took part in the 2005 National Health ...
... ... , ... (Vocus) April 21, 2010 -- SafeShot Technologies, LLC , a leader in safety ... Emeritus Professor of Surgery at Keck School of Medicine, University of Southern California. Dr. ...
... Washington, DC -- For women with hormone receptor-positive breast ... daily dose of an anti-hormone drug will block the ... breast cancer at bay. The treatments work like ... resistant to therapy. With no other treatment options, ...
... clinical trials have shown that non-steroidal anti-inflammatory drugs ... colon cancer and precancerous polyps in humans. Now, ... that an investigational form of naproxen, called nitric ... earliest molecular changes that lead to colorectal cancer ...
... taken a major step forward in the understanding of ovarian ... Researchers have found that patients with hereditary ovarian cancer ... more likely to experience secondary tumours in their liver and ... is better than other patients. In non-hereditary cancer, ovarian ...
Cached Medicine News:Health News:Researchers identify a new breast and ovarian cancer susceptibility gene 2Health News:Few Over 50 Get Skin Cancer Screenings 2Health News:SafeShot Technologies Names Dr. Robert W. Beart as New Chief Executive Officer 2Health News:SafeShot Technologies Names Dr. Robert W. Beart as New Chief Executive Officer 3Health News:1 big problem with many possible solutions 2Health News:1 big problem with many possible solutions 3Health News:1 big problem with many possible solutions 4Health News:1 big problem with many possible solutions 5Health News:1 big problem with many possible solutions 6Health News:1 big problem with many possible solutions 7Health News:Researchers show that nitric oxide-donating naproxen can boost colorectal cancer prevention 2Health News:Ovarian cancer study offers vital clues for new therapies 2
... biolitecs 980nm Diode Laser Series, ... 980 Lasers, are ideal for soft-tissue ... environments.,With unsurpassed, optimal absorption in water ... series allow controlled tissue ablation and ...
... diode laser is a versatile and durable ... tissue applications. With excellent hemostatic and ablative ... fiber optic delivery system that allows optimal ... alike.,Compact and portable, the Ceralas D15/810 is ...
... The TonoPach is a device intended for ... IOP remains the single most important metric ... However, as discovered in a large, ... study published in mid-2002, the patients central ...
Culture Confirmation Tests...
Medicine Products: